doi.org/10.1016/s1470-2045(22)00019-5

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study

..., Kenneth C. Anderson
182
The Lancet Oncology35.90
Volume: 23, Issue: 3, Pages: 416 - 427
Published: Feb 10, 2022
Paper Fields
Paper Details
Title
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
DOI
doi.org/10.1016/s1470-2045(22)00019-5
Published Date
Feb 10, 2022
Journal
The Lancet Oncology
Volume
23
Issue
3
Pages
416 - 427
© 2026 Pluto Labs All rights reserved.